WO2003070162A3 - Par-3 compounds for therapy and diagnosis and methods for using same - Google Patents

Par-3 compounds for therapy and diagnosis and methods for using same Download PDF

Info

Publication number
WO2003070162A3
WO2003070162A3 PCT/US2002/005322 US0205322W WO03070162A3 WO 2003070162 A3 WO2003070162 A3 WO 2003070162A3 US 0205322 W US0205322 W US 0205322W WO 03070162 A3 WO03070162 A3 WO 03070162A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
par
diagnosis
therapy
compounds
Prior art date
Application number
PCT/US2002/005322
Other languages
French (fr)
Other versions
WO2003070162A2 (en
Inventor
Charles A Nicolette
Original Assignee
Genzyme Corp
Charles A Nicolette
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Charles A Nicolette filed Critical Genzyme Corp
Priority to PCT/US2002/005322 priority Critical patent/WO2003070162A2/en
Priority to AU2002254010A priority patent/AU2002254010A1/en
Publication of WO2003070162A2 publication Critical patent/WO2003070162A2/en
Publication of WO2003070162A3 publication Critical patent/WO2003070162A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Abstract

The present invention provides methods and compositions for detecting, diagnosing, prognosing and monitoring the progress of PAR-3 related cancers and malignancies and kits for use in said methods. Further provided are methods for screening to identify agonists and antagonist of cancer antigens associated with PAR-3-related cancers and malignancies.
PCT/US2002/005322 2002-02-19 2002-02-19 Par-3 compounds for therapy and diagnosis and methods for using same WO2003070162A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/US2002/005322 WO2003070162A2 (en) 2002-02-19 2002-02-19 Par-3 compounds for therapy and diagnosis and methods for using same
AU2002254010A AU2002254010A1 (en) 2002-02-19 2002-02-19 Par-3 compounds for therapy and diagnosis and methods for using same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/005322 WO2003070162A2 (en) 2002-02-19 2002-02-19 Par-3 compounds for therapy and diagnosis and methods for using same

Publications (2)

Publication Number Publication Date
WO2003070162A2 WO2003070162A2 (en) 2003-08-28
WO2003070162A3 true WO2003070162A3 (en) 2004-06-17

Family

ID=27752553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/005322 WO2003070162A2 (en) 2002-02-19 2002-02-19 Par-3 compounds for therapy and diagnosis and methods for using same

Country Status (2)

Country Link
AU (1) AU2002254010A1 (en)
WO (1) WO2003070162A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2714071T3 (en) * 2011-05-24 2019-09-16 Biontech Rna Pharmaceuticals Gmbh INDIVIDUALIZED VACCINES AGAINST CANCER

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6338945B1 (en) * 1996-03-20 2002-01-15 Genzyme Corporation Method for identifying cytotoxic T-cell epitopes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6338945B1 (en) * 1996-03-20 2002-01-15 Genzyme Corporation Method for identifying cytotoxic T-cell epitopes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOBERTY ET AL.: "The cell-polarity protein Par6 links Par3 and a typical protein kinase C to Cdc42", NATURE CELL BIOLOGY, vol. 2, August 2000 (2000-08-01), pages 531 - 539, XP001086680 *
WELSH ET AL.: "Analysis of gene expression identifies candidate markers and pharmacological targets of prostate cancer", CANCER RESEARCH, vol. 61, 15 August 2001 (2001-08-15), pages 5974 - 5978, XP002251017 *
WELSH ET AL.: "Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer", PROC. NATL. ACAD. SCI. USA, vol. 98, no. 3, 30 January 2001 (2001-01-30), pages 1176 - 1181, XP002975970 *

Also Published As

Publication number Publication date
WO2003070162A2 (en) 2003-08-28
AU2002254010A1 (en) 2003-09-09
AU2002254010A8 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
WO2006078911A3 (en) Gitr antibodies for the diagnosis of nsclc
WO2006012646A3 (en) Amacr cancer markers
WO2005104810A3 (en) Novel therapeutic targets in cancer
WO2004060302A3 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2004074320A3 (en) Therapeutic targets in cancer
WO2005031001A3 (en) Novel therapeutic targets in cancer
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
WO2004111641A3 (en) Methods for detecting cancer and monitoring cancer progression
WO2007048978A3 (en) Method for detecting cancer
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
WO2008150496A3 (en) Assay for sensitivity to chemotherapeutic agents
WO2010093742A8 (en) Methods and compositions for identifying, classifying and monitoring subject having bcl-2 family inhibitor-resistant tumors and cancers
WO2002035232A3 (en) Method for detecting ovarian cancer based on human kallikrein 6 (hk6)
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
WO2004060304A3 (en) Novel compositions and methods in cancer
WO2004058146A3 (en) Novel compositions and methods in cancer
MX2007004342A (en) Cop1 molecules and uses thereof.
WO2002080844A3 (en) Novel bgp compounds for therapy and diagnosis and methods for using same
WO2005107396A3 (en) Novel compositions and methods in cancer
WO2007075672A3 (en) Prognostic cancer markers
WO2003080808A3 (en) Novel compositions and methods in cancer
EP2204376A3 (en) Novel therapeutic targets in cancer
WO2002055555A3 (en) Antigenic ck-18 compounds for therapy and diagnosis and methods for using same
EP1572225A4 (en) Thrombospondin fragments and uses thereof in clinical assays for cancer and generation of antibodies and other binding agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP